Price recently interviewed the CEO and Founder of C3® International, Inc., the makers of Idrasil™: Steele Clarke Smith III. Smith was on to discuss the Idrasil™ launch as the first standardized form of prescription medical cannabis in a pill. C3® International, a biopharmaceutical firm in the emerging cannabinoid therapeutics sector of healthcare, officially introduced this safer alternative to opiates and narcotics earlier this month.
Idrasil™ is a medical phenomenon because it treats a wide range of ailments and pain stemming from AIDS, anorexia, arthritis, autism, anxiety/depression, cancer, chronic pain, glaucoma, migraines, persistent muscle spasms; Parkinson’s disease, seizures, severe nausea, and Tourette’s syndrome. Idrasil™ also offers relief for patients struggling with clinical endocannabinoid deficiencies (CECD). It treats any other chronic or persistent medical symptom that substantially limits major life activities as per the Americans with Disabilities Act of 1990. Idrasil™ is currently available only in California, but with state and federal laws quickly changing, availability is expected to broaden substantially over time. Idrasil™ is aseptically processed and bacteria-free with a manufacturing process that is FDA-compliant. Idrasil™ consists of a proprietary blend of concentrated cannabis extract that is 100% natural and organic.